益生菌
心肌梗塞
医学
双歧杆菌
促炎细胞因子
坏死
嗜酸乳杆菌
炎症
纤维化
乳酸菌
病理
内科学
生物
食品科学
细菌
发酵
遗传学
作者
Samad Farashi Bonab,Saeed Tahmasebi,Soudeh Ghafouri‐Fard,Solat Eslami
出处
期刊:Apmis
[Wiley]
日期:2024-10-17
卷期号:133 (1)
摘要
Although there is a bulk of evidence on the favorable effect of probiotics on the cardiac system, their role in the management of myocardial infarction is not clear. Three viable probiotic bacterial strains, namely Lactobacillus reuteri, Bifidobacterium longum, and Bifidobacterium lactis, were gavaged to the rats daily for 28 days prior to the induction of myocardial injury. Myocardial injury was induced by the use of isoproterenol (ISO) in the probiotics, control and sham groups. The heart tissues were catheterized to evaluate the histopathological parameters and measure the expression of genes related to inflammation. Treatment with ISO caused subendocardial necrosis and rupture of cardiac myofibrils. Pretreatment with probiotics reduced the size of myocardial infarction caused by ISO. Also, in the probiotic group, a relative decrease in the amount of tissue fibrosis and rupture of cardiomyocytes fibers was seen. Pretreatment with probiotics partially ameliorated myocardial necrosis, edema and leukocyte infiltration. Also, a remarkable decrease was detected in the expression of tissue proinflammatory genes in the pretreated group with probiotics. Thus, viable probiotic supplementation may ameliorate or prevent cardiac injury. Additional preclinical and clinical studies are required to clarify the impact of probiotics in the prevention and management of cardiovascular disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI